EQRx

EQRx (Nasdaq: EQRX or EQRXW) is a first-of-a-kind company that is revolutionizing the way medicines are discovered, developed, and brought to people.

eqrx.com
Cambridge, MA

CEO: Melanie Nallicheri
Arboretum Lead: Jan Garfinkle

IN THE NEWS

May 8, 2023 in EQRx

EQRx Resets to Focus on Clinically Differentiated Medicines, Leveraging $1.3 Billion Cash Position

EQRx, Inc. (Nasdaq: EQRX), recently announced plans to reset its business and reported financial results for the first quarter ended March 31, 2023.

February 23, 2023 in EQRx, News Page

EQRx Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Progress

December 2, 2022 in EQRx, News Page

EQRx Announces Acceptance of Marketing Authorization Application by the European Medicines Agency

Application is based on data from the pivotal Phase 3 AENEAS trial evaluating aumolertinib as first-line treatment of patients with EGFR-mutated non-small cell lung cancer.

August 11, 2022 in EQRx, News Page

EQRx Reports Second Quarter 2022 Financial Results and Recent Corporate Progress

EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at radically lower prices, today reported financial results for the second quarter…